Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Reports 5.7-Percent Increase in Q3 Revenue Amid Narrowed Losses

NEW YORK, Nov. 1 (GenomeWeb News) - Caliper today reported a 5.7-percent year-over-year revenue increase for the third quarter. The Hopkinton, Mass.-based biotech also narrowed its net loss by 25 percent.

 

For the quarter ended Sept. 30, Caliper reported revenues of $21.3 million, compared to $20.2 million in the third quarter of 2004. Of this, approximately $15.8 million was product revenue, while the rest resulted from service, contract, and license fees.

 

The company spent $4.2 million on R&D in the period, down from $5.2 million year over year.

 

Caliper's net losses for the quarter decreased to $3.9 million from $5.1 million in the same quarter last year.

 

As of Sept. 30, Caliper had cash, cash equivalents, and marketable securities of $34.8 million.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.